Piramal Pharma completes acquisition of Hemmo Pharma for Rs 775 crore
New Delhi: Piramal Enterprises on Wednesday said its subsidiary, Piramal Pharma, has completed the acquisition of Hemmo Pharmaceuticals.
"Piramal Pharma Ltd has completed the acquisition of Hemmo," Piramal Enterprises said in a regulatory filing.
In March this year, Piramal Pharma Ltd entered into an agreement to acquire a 100 per cent stake in Hemmo Pharmaceuticals for an upfront consideration of Rs 775 crore and earn-outs linked to the achievement of milestones.
With the addition of Hemmo's capabilities, Piramal Pharma will gain access to the growing peptide Active Pharmaceutical Ingredient (API) market and enhance its ability to offer integrated services to its customers globally, Piramal Pharma had said in a statement in March.
Read also: Piramal to cover COVID vaccination costs for employees taking jabs in India
